|
BioPharma Credit PLC - life sciences debt investment trust - Says had $110 million investment in Epizyme Inc in form of senior secured loan. ‘The loan was made in four different tranches and each tranche had different prepayment economics,’ BioPharma adds. Ipsen on Friday completed acquisition of biopharmaceutical firm Epizyme. BioPharma says has received $119 million, including $9 million prepayment and make-whole fees. Realises internal rate of return of just over 15%.
Current stock price: $0.97
12-month change: down 1.0%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
